The influence of H. pylori infection in HER2-positive gastric cancer cell lines: insights from Wnt/β-catenin pathway

QR Code

The influence of H. pylori infection in HER2-positive gastric cancer cell lines: insights from Wnt/β-catenin pathway

IntroductionThe impact of H. pylori infection on the efficacy of trastuzumab in HER2-positive gastric cancer (GC) remains poorly understood, despite growing evidence that tumor microenvironment and host-pathogen interactions influence therapeutic outcomes. This study aimed to investigate how H. pylo...

Full description

Saved in:

Bibliographic Details
Main Authors:	Valli De Re, Mariateresa Casarotto, Giulia Brisotto, Stefania Zanussi, Mariangela De Zorzi, Ombretta Repetto, Elena Muraro, Paola Spessotto, Paolo Baldo, Vito Racanelli, Marco Vincenzo Lenti, Marino Venerito, Matteo Fassan, Agostino Steffan, Stefano Realdon, Renato Cannizzaro
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Immunology
Subjects:	Helicobacter pylori trastuzumab HER2 gastric cancer Wnt PD-L1/PD-L2
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1550651/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Synthesis and Evaluation of [<sup>18</sup>F]AlF-NOTA-iPD-L1 as a Potential Theranostic Pair for [<sup>177</sup>Lu]Lu-DOTA-iPD-L1
by: Guillermina Ferro-Flores, et al.
Published: (2025-07-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

IRF4 Mediates Immune Evasion to Facilitate EBV Transformation
by: Ling Wang, et al.
Published: (2025-06-01)

Modern possibilities of using immunotherapy in the treatment of cervical cancer
by: A. V. Tarasova, et al.
Published: (2021-09-01)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
by: Otgontuya Ganbaatar, et al.
Published: (2021-12-01)

Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty
by: Meshach Asare-Werehene, et al.
Published: (2025-07-01)

Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment
by: A. Yu. Kalinchuk, et al.
Published: (2024-03-01)

Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
by: Tian Zeng, et al.
Published: (2019-12-01)

Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer
by: Linsong Mu, et al.
Published: (2019-12-01)

Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors
by: Wenke Li, et al.
Published: (2025-07-01)

Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment
by: Rishi Kant, et al.
Published: (2025-06-01)

Involvement of the Programmed Death 1/Programmed Death Ligand 1 Pathway in the Immune Microenvironment of Chronic Periapical Lesions
by: Yujin Song, et al.
Published: (2025-08-01)

ROLE OF PD-L1 ASSESSMENT IN THE ASPECT OF MOLECULAR-GENETIC CLASSIFICATION OF COLORECTAL CANCER. CURRENT STATE OF THE PROBLEM
by: S. V. Vtorushin, et al.
Published: (2021-03-01)

Cancer therapeutic implications of microRNAs in the regulation of immune checkpoint blockade
by: Yan Zhang, et al.
Published: (2019-08-01)

The prognostic role of Claudin 18.2 in advanced gastric or gastroesophageal junction adenocarcinoma: a systematic literature review
by: M. Fassan, et al.
Published: (2025-09-01)

Prognostic significance of PD-L1 expression and evaluation of microsatellite instability status in patients with retroperitoneal leiomyosarcomas
by: V. Е. Bugaev, et al.
Published: (2019-11-01)

The predictive value of total body PET/CT in high PD-L1 expression and immunotherapy in advanced non-small cell lung cancer patients
by: Huibin Jin, et al.
Published: (2025-07-01)

Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patients
by: Yirui Zhai, et al.
Published: (2025-08-01)

MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER
by: R. A. Gafanov, et al.
Published: (2018-03-01)

Ligand-associated activation of vitamin D receptors and potential points of application of its effects in the morphogenesis of immune inflammation: Literature review
by: E. T. Ablyakimov, et al.
Published: (2024-07-01)

Integrating clinical trial landscapes and bibliometric analysis: unveiling the impact of PD-1/PD-L1 inhibitors on renal cell carcinoma research and therapeutic trajectories summary
by: Yuanbin Huang, et al.
Published: (2025-07-01)

Metabolism of tryptophan in non-small lung cancer patients with different effect of PD-1 / PD-L1 inhibitors immunotherapy
by: E. Yu. Zlatnik, et al.
Published: (2022-06-01)

PREDICTIVE RESPONSE MARKERS FOR IMMUNE RESPONSE BLOCKS
by: G. A. Janus, et al.
Published: (2020-09-01)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
by: Miao Wang, et al.
Published: (2021-12-01)

Subpopulation composition of PD-L1-positive lymphocytes in the primary tumour in luminal breast cancer patients
by: L. A. Tashireva, et al.
Published: (2024-07-01)

Distinct Roles of HHLA2 and PD-L1 in the Immune Cell and Prognosis of Hepatocellular Carcinoma
by: Wang CH, et al.
Published: (2025-07-01)

Programmed Death Ligand 1 Modulation by Bacillus Calmette-Gu&eacute;rin and Toll-Like Receptor Agonists in Distinct Breast Cancer Cell Subtypes
by: Barbosa G, et al.
Published: (2025-06-01)

Influence of Different Nicotine Sources on Exercise-Driven Immune Responses of Peripheral Blood Monocytes
by: Paul N. Axt, et al.
Published: (2025-06-01)

The regulatory effects of PD-1/PD-L1 inhibitors on bone metabolism: opportunities and challenges in osteoporosis management
by: Jia-Wen Wang, et al.
Published: (2025-07-01)

Bimodal onset and pan-cancer uniformity of immune-mediated liver injury: a retrospective cohort study
by: Jiaojiao Song, et al.
Published: (2025-07-01)

Mapping the immunological landscape and emerging immunotherapeutic strategies in cervical cancer: a comprehensive review
by: Xinyi Zhang, et al.
Published: (2025-07-01)

Subpopulations of B lymphocytes in patients with breast cancer depending on the PD-L1 status
by: L. A. Tashireva, et al.
Published: (2023-04-01)

Microsatellite Instability Status and Programmed Death Cell Ligand 1 Expression in Serous Ovarian Tumors
by: Gizem TEOMAN, et al.
Published: (2025-07-01)

Polygonatum polysaccharides as gut microbiota modulators: implications for autophagy-dependent PD-L1 clearance in cancer immunotherapy
by: Yongjie Li, et al.
Published: (2025-06-01)

<i>PD-L1</i> and <i>PD-L2</i> gene expression in human glioblastoma cells resistant to chemo- and radiotherapy
by: A. A. Pinevich, et al.
Published: (2023-06-01)

The features of PD-L1 expression in tumor stromal cells, peritumoral microvessels and isolated clusters of tumor cells in breast cancer tissue and their correlation with clinical and morphological characteristics of breast cancer
by: E. Yu. Zubareva, et al.
Published: (2023-11-01)

Ginseng-Derived Exosomes Attenuate Immune Evasion in NSCLC via PD-L1 Modulation
by: Zhu LJ, et al.
Published: (2025-07-01)

The investigation of PD-L1 expression as a prognostic marker for uterine sarcoma.
by: V. S. Sukhin, et al.
Published: (2018-08-01)

PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib
by: Yingfang Feng, et al.
Published: (2025-07-01)

The DNA mismatch repair protein, MSH6 is a novel regulator of PD-L1 expression
by: Kirsten Brooksbank, et al.
Published: (2025-09-01)